Cartesian Therapeutics, Inc. RNAC

Healthcare SIC 2834 - Pharmaceutical Preparations Nasdaq

The Company (formerly known as Selecta Biosciences, Inc., or Selecta) was incorporated in Delaware on December 10, 2007, and is headquartered in Frederick, Maryland. On November 13, 2023, the Company and the Delaware corporation which, immediately prior to the Merger (as defined below), was known as Cartesian Therapeutics, Inc., or Old Cartesian, entered into an Agreement and Plan of Merger, or the Merger Agreement, by and among the Company, Sakura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company, or First Merger Sub, Sakura Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company, or Second Merger Sub, and Old Cartesian. Pursuant to the Merger Agreement, and simultaneously with execution thereof, (i) First Merger Sub merged with and into Old Cartesian, pursuant to which Old Cartesian was the surviving corporation, or the First Step Surviving Corporation, and became a wholly owned subsidiary of the Company, or the First Merger, and (ii) immediately following the First Merger, Old Cartesian (as the First Step Surviving Corporation) merged with and into Second Merger Sub, pursuant to which Second Merger Sub was the surviving company, or the Surviving Company, and continued under the name "Cartesian Bio, LLC", or the Second Merger and, together with the First Merger, the Merger. In connection with the Merger and pursuant to the Merger Agreement, the Company (which was known as Selecta Biosciences, Inc. until immediately prior to the Merger) changed its corporate name to Cartesian Therapeutics, Inc.

Last close 9.27 2026-09-04
Market cap $280.5M 2026-06-30 share count
52-week range 5.60 - 11.00

Valuation FY2025 figures against the last close

P/S701.2x
P/E
P/FCF
EV/EBITDA
Dividend yield
Diluted EPS-5.02

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $400.0K$38.3M$26.0M$110.8M$85.1M$16.6M$6.7M$903.0K$207.0K$8.1M
R&D $58.0M$45.1M$71.3M$72.4M$68.7M$54.5M$42.7M$47.7M$45.2M$29.7M
SG&A $31.5M$30.1M$40.5M$23.9M$20.9M$18.9M$16.4M$18.2M$18.8M$13.1M
Total operating expenses $146.2M$82.8M$112.4M$96.2M$89.7M$73.4M$59.1M$65.9M$64.0M$42.8M
Operating income -$143.4M-$43.9M-$86.4M$14.5M-$4.6M-$56.8M-$52.5M-$65.0M-$63.8M-$34.7M
Interest expense $0$2.8M$3.0M$2.8M$1.6M$1.5M$1.5M$1.2M$1.3M
Pre-tax income -$139.5M-$77.1M-$238.7M$34.8M-$9.7M-$68.9M-$55.4M
Income tax $9.2M$287.0K$19.0M$609.0K$16.0M$0$0
Net income -$130.3M-$77.4M-$219.7M$35.4M-$25.7M-$68.9M-$55.4M-$65.3M-$65.3M-$36.2M
EPS, basic -5.02-4.48-49.760.24-0.22-0.68-1.22
EPS, diluted -5.02-4.49-49.760.10-0.22-0.68-1.22-2.92-3.20-3.89
Shares, diluted (wtd. avg.) $26.0M$17.4M$5.2M$145.9M$114.3M$101.2M$45.5M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $125.1M$212.6M$78.3M$108.0M$114.1M$140.1M$91.6M$37.7M$71.0M$59.0M
Short-term investments $0$28.2M$14.0M$0$25.5M
Receivables $1.1M$872.0K$5.9M$6.6M$9.9M$7.2M$5.0M$0$215.0K
Total current assets $129.3M$216.6M$90.7M$148.1M$144.4M$151.3M$96.7M$42.1M$86.8M
Property, plant and equipment $12.2M$9.9M$2.1M$2.8M$2.1M$1.4M$1.2M$2.1M$2.0M
Goodwill $48.2M$48.2M$48.2M$0
Total assets $296.4M$435.0M$305.1M$165.9M$159.9M$165.4M$99.6M$44.5M$89.3M
Accounts payable $1.3M$288.0K$3.1M$316.0K$224.0K$443.0K$500.0K$1.1M$3.9M
Total current liabilities $14.9M$23.0M$68.2M$25.1M$72.3M$81.5M$34.9M$35.1M$13.7M
Total liabilities $422.7M$441.8M$444.7M$72.1M$137.4M$183.4M$91.2M$49.9M$34.3M
Retained earnings -$822.4M-$692.1M-$614.6M-$394.9M-$430.3M-$404.6M-$335.8M-$280.4M-$151.6M
Total equity -$126.2M-$6.8M-$440.2M$93.8M$22.5M-$18.0M$8.4M-$5.4M$51.8M$55.0M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$73.9M-$23.7M-$51.2M-$31.6M-$60.4M$34.9M-$51.4M-$59.2M-$52.0M-$19.8M
Depreciation and amortisation $2.4M$1.2M$700.0K$700.0K$600.0K$600.0K$700.0K$1.0M$750.0K$802.0K
Stock-based compensation $10.5M$6.6M$22.5M$11.2M$7.7M$5.4M$5.2M$5.7M$4.1M
Capital expenditure $5.5M$9.1M$206.0K$1.2M$1.1M$815.0K$47.0K$884.0K$733.0K$586.0K
Investing cash flow -$5.5M-$8.7M$34.6M-$15.0M-$17.1M-$741.0K$229.0K$25.3M-$2.1M-$22.1M
Financing cash flow -$8.1M$168.4M-$13.1M$39.2M$52.9M$14.4M$105.0M$697.0K$66.0M$67.7M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001453687-26-000072.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
AKTX Akari Therapeutics Plc $1.79T
LLY ELI LILLY & Co $1.08T 50.1x 44.7%
JNJ JOHNSON & JOHNSON $663.28B 25.0x 6.0%
ONC BeOne Medicines Ltd. $529.55B 1,885.6x 40.2%
ABBV AbbVie Inc. $453.19B 108.7x 8.6%
MRK Merck & Co., Inc. $370.89B 20.6x 1.3%
ABT ABBOTT LABORATORIES $188.69B 29.1x 5.7%
PFE PFIZER INC $162.16B 20.9x -1.6%